Tetracyclic atypical antidepressant (NaSSA)
A noradrenergic and specific serotonergic antidepressant; a tetracyclic with strong H1 antihistamine activity producing pronounced sedation and appetite stimulation.
Abstract
Mirtazapine ((R/S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; CAS 85650-52-8; molecular formula C17H19N3; molecular weight 265.36) is a tetracyclic NaSSA (noradrenergic and specific serotonergic antidepressant) developed at Organon and approved by the FDA in 1996 under the trade name Remeron. Mechanism distinguishes the compound from the SSRI/SNRI class: rather than inhibiting transporters, mirtazapine antagonizes presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, increasing both norepinephrine and serotonin release. Concurrent 5-HT2A and 5-HT2C antagonism redirects the released serotonin preferentially to 5-HT1A receptors. Strong H1 histamine antagonism (Ki approximately 0.14 nM, comparable to first-generation antihistamines) produces sedation and weight gain, often dose-limiting at higher doses. The compound has minimal activity at muscarinic, dopaminergic, or transporter sites. Plasma half-life is 20 to 40 hours; metabolism is via CYP2D6, CYP3A4, and CYP1A2. Approved for major depressive disorder; widely used off-label for insomnia and as an appetite stimulant. Used as a reference compound in alpha-2 adrenergic and 5-HT2 receptor pharmacology.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.